Pasireotide (SOM230) is Effective for the Treatment of Pancreatic Neuroendocrine Tumors (PNETs) in a Multiple Endocrine Neoplasia Type 1 (MEN1) Conditional Knockout Mouse Model

BACKGROUND: Pasireotide (SOM230), a long acting somatostatin analogue (LAR) has improved agonist activity at somatostatin receptors. We tested the effect of SOM230 on insulin secretion, glucose levels, tumor growth, and survival using an MEN1 transgenic mouse model. METHODS: Eight 12 month-old condi...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Quinn, Thomas J., Yuan, Ziqiang, Adem, Asha, Geha, Rula, Vrikshajanani, Chakravarthy, Koba, Wade, Fine, Eugene, Hughes, David T., Schmid, Herbert, Libutti, Steven K.
Formato: Artigo
Lenguaje:Inglês
Publicado: 2012
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC3732168/
https://ncbi.nlm.nih.gov/pubmed/23102680
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.surg.2012.08.021
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares